Sofusbuvir and Ribavirin for children with hepatitis C infection (3-12 yrs, genotype 2 or 3) P Rosenthal et al. Hepatology 2020; 71: 31-43. n=54. SVR12 was 98% (one patient did not complete treatment).
Alpha-one antitrypsin heterozygositiy contributes to cirrhosis in fatty liver disease. Liver Transplantation 2020; 26: 17-24. From the discussion: “unexpected PASD+ globules, in the context of advanced liver disease, are a specific finding that indicates the presence of a mutant A1AT allele.” Of 196 explanted livers from NASH patients, 21 (11%) has PASD+ globules; however, among NASH patients the frequency was 47%. Also, the Z allele was present in 10% of all tested liver explants, this exceeds the 2% rate in the general population. Thus, in agreement with other studies, A1AT heterozygosity contributes to chronic liver failure, but may affect fatty liver disease more than other chronic liver diseases.
Durability of HBsAg Loss in Hepatitis B AS Alawad et al. Clin Gastroenterol Hepatol 2020;18: 700-09. In this retorspective study form NIH, 89/787 HBsAg-positive patients cleared HBsA; 65 had confirmed clearance. (spontaneous in 19, post-interferon in 22, and post-NA treatment in 24). 62 of 65 remained negative after a mean time of 9.6 years. 3 patients had seroreversion at a mean of 20 months after stopping therapy, though this was transient in 2 of 3 and may have been a false-positive.
Are Medications Contributing to Obesity and Fatty Liver Disease? ~25% of U.S. adults take a prescription medication that often produces obesity as an adverse effect. (Hales CM et al. Obesity Week 2019, Link to Abstract T-OR-2037). PRESCRIPTION MEDICATIONS THAT PROMOTE WEIGHT GAIN: Prevalence of Use Among U.S. Adults, 2013-2016 Common obesogenic medications in this cohort, (n=11,055), included all glucocorticoids, beta-blockers, and antihistamines and some agents among antidepressants, antipsychotics, antidiabetics and progestin-only contraceptives. Medications were defined as promoting weight gain according to the Endocrine Society Clinical Practice Guideline for the Pharmacological Management of Obesity (J Clin Endocrinol Metab, 2015).
If you have not seen this on YouTube, highly recommend this virtual choir link: Rodean School -Hallelujah
More fallout from Coronavirus: NY Times: Coronavirus May Add Billions to Nation’s Health Care Bill Insurance premiums could spike as much as 40 percent next year, a new analysis warns, as employers and insurers confront the projected tens of billions of dollars in additional costs of treating coronavirus patients.
Topical (& Tasty) Tweets:
Pingback: COVID-19 Posts | gutsandgrowth
Pingback: NY Times: How Will We Know When to Reopen the Country? & Timely Tweets | gutsandgrowth
Pingback: COVID-19 Daily Deaths & Asymptomatic Infections | gutsandgrowth
Pingback: “Quietly” Testing Famotidine for COVID-19 | gutsandgrowth
Pingback: Alpha-1-Antitrypsin Deficiency | gutsandgrowth
Pingback: Insight Into Alpha-1 Antitrypsin Heterozygosity | gutsandgrowth
Pingback: Liver Shorts -February 2021 (part 1) | gutsandgrowth